Sponsor
AbbVie
61 PBAC submissions on file, active 2013–2025. 85% have been recommended.
Submissions
61
2013 → 2025
Win rate
85 %
51 recommended of 60 bucketable
Drugs
14 · 11 listed
unique molecules submitted
PBS spend captured
$171M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Rheumatology 14 Dermatology 11 Gastroenterology 10 Haematology 9 Hepatology 5 Neurology 4 Oncology 3 Ophthalmology 2 Endocrinology 2 Immunology 1
Activity by year 2013 (2) · 2014 (3) · 2015 (5) · 2016 (7) · 2017 (8) · 2018 (3) · 2019 (6) · 2020 (4) · 2021 (7) · 2022 (5) · 2023 (4) · 2024 (6) · 2025 (1)
Rejection patterns
Across 7 Not recommended decisions on file.
1× economic analysis highly uncertain and unable to provide a reliable estimate of cost-effectiveness1× model structure not appropriate (treatment costs not linked to health states1× model maintained continued response beyond trial duration while patients not being treated)1× high sensitivity to efficacy and utility values1× uncertain applicability of trial results to requested PBS population due to differences in dose regimen and continuation rulesOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.